Moreover, vimentin has been described as a negative prognostic marker in various cancers (Dongre and Weinberg, 2019), and also in NSCLC, as extensively documented by numerous studies, then pooled in a meta-analysis (Ye et al., 2016). This evidence concerns the gene VIM and cancer.